SOURCE: Active Biotech

November 14, 2008 02:30 ET

Active Biotech AB Interim Report January-September 2008

LUND, SWEDEN--(Marketwire - November 14, 2008) -


- Laquinimod -- positive data presented from extension study

- 57-57 -- Clinical Phase II/III trial to commence in 2009

- RhuDex® -- Additional preclinical tests under way

- ANYARA -- Phase III study proceeding as planned

- TASQ -- Phase II study proceeding as planned

- Net sales SEK 8.8 M (8.7)

- Operating loss SEK 167.0 M (loss: 147.8 )

- Loss after tax SEK 162.0 M (loss: 152.0)

- Loss per share for the period amounted to SEK 3.30 (loss: 3.30)


For further information, please contact:
Tomas Leanderson
President and CEO
Tel: +46 (0)46-19 20 95

Göran Forsberg
VP Investor Relations & Business Development
Tel: +46 (0)46-19 11 54

Hans Kolam
CFO
Tel: +46 (0)46-19 20 44

Active Biotech AB
(Corp. Reg. No. 556223-9227)
PO Box 724, SE-220 07 Lund
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 00

This report is also available at www.activebiotech.com


This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.



Copyright © Hugin AS 2008. All rights reserved.

Contact Information